IRINOTECAN FOR CHILDREN WITH RELAPSED SOLID TUMORS

Autor:	Yoshiaki Tsuchida, Atsushi Manabe, Akira Shimada, Masahito Tsurusawa, Tohru Sugimoto, Keisei Kawa, Hideo Mugishima, Toshiji Shitara, Jun Ichi Mimaya, Ryoji Hanada, Tadashi Matsunaga
Rok vydání:	2006
Předmět:	Oncology Leiomyosarcoma medicine.medical_specialty business.industry Hematology Undifferentiated sarcoma medicine.disease body regions Irinotecan Internal medicine Partial response Primitive neuroectodermal tumor Neuroblastoma Pediatrics Perinatology and Child Health medicine business Rhabdomyosarcoma neoplasms medicine.drug Tumor marker
Zdroj:	Pediatric Hematology and Oncology. 23:103-110
ISSN:	1521-0669 0888-0018
Popis:	Irinotecan is expected to become a new drug for childhood solid tumors. Sixteen children with relapsed solid tumors received irinotecan 180 mg/m2/day for 3 consecutive days, repeated once after 25 days off. Their original tumors were neuroblastoma in 7, rhabdomyosarcoma in 3, nephroblastoma and undifferentiated sarcoma in 2 each, and primitive neuroectodermal tumor and leiomyosarcoma in 1 each. The average age at trials was 6 years. Partial response was achieved in 5 (31.3%) (neuro-blastoma, rhabdomyosarcoma, nephroblastoma, undifferentiated sarcoma, and leiomyosarcoma), and decrease in tumor marker in the other 2. Irinotecan appears promising, and could become included in the first-line treatment.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::9b76df4a1267af4fd418fde965f5c4a4 https://doi.org/10.1080/08880010500457152 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.